ADT achieved surgically or chemically (with luteinizing hormone-releasing hormone (LHRH) agonists, LHRH antagonists, or anti-androgens) is the mainstay therapeutic modality for the treatment of advanced PCa. Here, GNRH1 is linked to posterior cortical atrophy.